Cyclacel appoints Dr Nicholas Bacopoulos to Board
This article was originally published in Scrip
Executive Summary
Cyclacel Pharmaceuticals, a US biopharmaceutical company discovering, developing and commercialising mechanism-targeted drugs to treat cancer and other serious disorders, has appointed Dr Nicholas Bacopoulos to its board of directors. Dr Bacopoulos's previous leadership roles include CEO and president of Aton Pharma (a company subsequently acquired by Merck), where he led the development of Zolinza. He was formerly president and head of R&D at OSI Pharmaceuticals, where he was involved with the global development of Tarceva, approved for the treatment of non-small cell lung and pancreatic cancers.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.